BRPI1011314A2 - conjugados de albumina-peptídeo amilóide e usos dos mesmos - Google Patents
conjugados de albumina-peptídeo amilóide e usos dos mesmosInfo
- Publication number
- BRPI1011314A2 BRPI1011314A2 BRPI1011314A BRPI1011314A BRPI1011314A2 BR PI1011314 A2 BRPI1011314 A2 BR PI1011314A2 BR PI1011314 A BRPI1011314 A BR PI1011314A BR PI1011314 A BRPI1011314 A BR PI1011314A BR PI1011314 A2 BRPI1011314 A2 BR PI1011314A2
- Authority
- BR
- Brazil
- Prior art keywords
- albumin
- amyloid peptide
- peptide conjugates
- conjugates
- amyloid
- Prior art date
Links
- 239000000863 peptide conjugate Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382078A EP2258398A1 (en) | 2009-05-26 | 2009-05-26 | Albumin-amyloid peptide conjugates and uses thereof |
| PCT/EP2010/057235 WO2010136487A1 (en) | 2009-05-26 | 2010-05-26 | Albumin-amyloid peptide conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011314A2 true BRPI1011314A2 (pt) | 2016-03-15 |
Family
ID=41022577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011314A BRPI1011314A2 (pt) | 2009-05-26 | 2010-05-26 | conjugados de albumina-peptídeo amilóide e usos dos mesmos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9023991B2 (pt) |
| EP (2) | EP2258398A1 (pt) |
| JP (2) | JP5936539B2 (pt) |
| KR (1) | KR101459080B1 (pt) |
| CN (1) | CN102458478B (pt) |
| AR (1) | AR076892A1 (pt) |
| AU (1) | AU2010251961B2 (pt) |
| BR (1) | BRPI1011314A2 (pt) |
| CA (1) | CA2763569C (pt) |
| DK (1) | DK2435093T3 (pt) |
| ES (1) | ES2587962T3 (pt) |
| HU (1) | HUE030218T2 (pt) |
| IL (1) | IL216626A (pt) |
| MX (1) | MX2011012677A (pt) |
| PL (1) | PL2435093T3 (pt) |
| PT (1) | PT2435093T (pt) |
| RU (1) | RU2533806C2 (pt) |
| TW (1) | TWI524900B (pt) |
| WO (1) | WO2010136487A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013021353A1 (en) * | 2011-08-11 | 2013-02-14 | Bar-Ilan University | Surface modified proteinaceous spherical particles and uses thereof |
| CN103450347A (zh) * | 2012-05-29 | 2013-12-18 | 四川百利药业有限责任公司 | 一种用于治疗阿尔兹海默症的多肽及基因疫苗 |
| CN105315361A (zh) * | 2014-07-29 | 2016-02-10 | 天津大学 | 一种酸化白蛋白及制备方法和在抑制β-淀粉样蛋白聚集的应用 |
| ES2571055B1 (es) * | 2016-02-15 | 2016-12-28 | Araclon Biotech, S.L. | Conjugado amiloide y usos y procedimientos del mismo |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| CN115715809A (zh) * | 2022-11-24 | 2023-02-28 | 武汉禾元生物科技股份有限公司 | 重组人血清白蛋白-药物偶联物 |
| KR20250125186A (ko) * | 2024-02-14 | 2025-08-21 | 국립부경대학교 산학협력단 | 알부민 고정 셀룰로오스 및 이를 포함하는 알츠하이머 치료용 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
| US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| JP4374316B2 (ja) * | 1993-01-25 | 2009-12-02 | 武田薬品工業株式会社 | β−アミロイドまたはその誘導体に対する抗体およびその用途 |
| EP0683234B2 (en) * | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| SI0994728T1 (sl) | 1997-04-09 | 2009-02-28 | Intellect Neurosciences Inc | Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo |
| US6809186B1 (en) | 1999-01-22 | 2004-10-26 | Martek Biosciences Corporation | Simple method for labeled conjugate production |
| US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| WO2001062284A2 (en) | 2000-02-21 | 2001-08-30 | Pharmexa A/S | Novel method for down-regulation of amyloid |
| US6926898B2 (en) * | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US6787636B1 (en) | 2000-07-14 | 2004-09-07 | New Century Pharmaceuticals, Inc. | Modified serum albumin with reduced affinity for nickel and copper |
| EP1975179A1 (en) * | 2001-12-26 | 2008-10-01 | Araclon Biotech, S.L. | Polyclonal antibodies, preparation method thereof and use of same |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| AU2003259965A1 (en) | 2002-08-20 | 2004-03-11 | Neurogenetics, Inc. | Methods and compositions for modulating amyloid beta |
| CA2508831C (en) | 2002-12-13 | 2012-05-01 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| ES2246177B1 (es) | 2003-05-08 | 2007-03-01 | Universidad De Zaragoza. | Uso de anticuerpos para el tratamiento de enfermedades amiloideas. |
| US20050255042A1 (en) | 2003-11-24 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer, University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| SI2336147T1 (sl) | 2003-12-17 | 2014-08-29 | Janssen Alzheimer Immunotherapy | Konjugati nosilcev a beta imunogenih peptidov in postopki izdelave istih |
| CN101665538A (zh) | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| JP2007522119A (ja) * | 2004-01-28 | 2007-08-09 | キュリックス エーピーエス | アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート |
| WO2005116260A2 (en) | 2004-05-25 | 2005-12-08 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| CA2604032C (en) | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| WO2006121656A2 (en) * | 2005-05-05 | 2006-11-16 | Merck & Co., Inc. | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| CA2607056C (en) | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US8106015B2 (en) * | 2007-04-20 | 2012-01-31 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method for enhancing immune response with peptide |
-
2009
- 2009-05-26 EP EP09382078A patent/EP2258398A1/en not_active Withdrawn
-
2010
- 2010-05-26 PT PT107243602T patent/PT2435093T/pt unknown
- 2010-05-26 US US13/322,417 patent/US9023991B2/en active Active
- 2010-05-26 CA CA2763569A patent/CA2763569C/en not_active Expired - Fee Related
- 2010-05-26 HU HUE10724360A patent/HUE030218T2/en unknown
- 2010-05-26 TW TW099116941A patent/TWI524900B/zh not_active IP Right Cessation
- 2010-05-26 BR BRPI1011314A patent/BRPI1011314A2/pt not_active Application Discontinuation
- 2010-05-26 JP JP2012512356A patent/JP5936539B2/ja not_active Expired - Fee Related
- 2010-05-26 DK DK10724360.2T patent/DK2435093T3/en active
- 2010-05-26 WO PCT/EP2010/057235 patent/WO2010136487A1/en not_active Ceased
- 2010-05-26 AU AU2010251961A patent/AU2010251961B2/en not_active Ceased
- 2010-05-26 EP EP10724360.2A patent/EP2435093B1/en active Active
- 2010-05-26 PL PL10724360.2T patent/PL2435093T3/pl unknown
- 2010-05-26 MX MX2011012677A patent/MX2011012677A/es active IP Right Grant
- 2010-05-26 KR KR1020117031061A patent/KR101459080B1/ko not_active Expired - Fee Related
- 2010-05-26 AR ARP100101822A patent/AR076892A1/es not_active Application Discontinuation
- 2010-05-26 CN CN201080031742.0A patent/CN102458478B/zh not_active Expired - Fee Related
- 2010-05-26 ES ES10724360.2T patent/ES2587962T3/es active Active
- 2010-05-26 RU RU2011153023/10A patent/RU2533806C2/ru active
-
2011
- 2011-11-27 IL IL216626A patent/IL216626A/en active IP Right Grant
-
2013
- 2013-09-20 US US14/032,830 patent/US9163062B2/en active Active
-
2014
- 2014-11-21 JP JP2014237014A patent/JP5985589B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1015918A2 (pt) | conjugados de peptídeo multiméricos e usos dos mesmos | |
| BRPI0923283A2 (pt) | conjugados terapêuticos de peptídeo e usos dos mesmos | |
| BR112012001260A2 (pt) | conjugados de epsilon-polilisina e o emprego dos mesmos | |
| BRPI1009455A2 (pt) | anticorpos anti-c40 e usos dos mesmos | |
| BR112012006501A2 (pt) | polipeptídios e usos dos mesmos | |
| BRPI0912225A2 (pt) | peptídeos de direcionamento lisossomais e usos dos mesmos | |
| BRPI0922790A2 (pt) | peptídeos de ligação sparc e usos dos mesmos | |
| BRPI0912198A2 (pt) | anticorpos anti-fn14 e usos dos mesmos | |
| BRPI1011404A2 (pt) | mutantes e usos dos mesmos | |
| BRPI0920927A2 (pt) | derivados de azaquinolinona e usos dos mesmos | |
| BRPI0922691A2 (pt) | conjugados de leptina e análogo de leptina e usos dos mesmos | |
| PT2531206T (pt) | Polipéptidos clorotoxina e conjugados e usos dos mesmos | |
| BR112012004731A2 (pt) | peptídeos derivados de wnt10 e uso dos mesmos | |
| BRPI0922689A2 (pt) | conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos | |
| BRPI0819909A2 (pt) | anticorpos antimesotelina e usos dos mesmos | |
| BRPI1014997A2 (pt) | compostos heteroarila e usos dos mesmos | |
| BRPI0821310A2 (pt) | Conjugados polipeptídeos-ácido nucleico e usos dos mesmos | |
| EP2427472A4 (en) | LIPOPHILIC POLYNUCLEOTIDE CONJUGATE | |
| BR112012002072A2 (pt) | polipeptídeos de fator ix modificados e usos dos mesmos | |
| BRPI1012340A (pt) | proteínas de ligação específica e usos das mesmas | |
| BRPI1010024A2 (pt) | derivados de aminopirrolidinona e uso dos mesmos | |
| BRPI0910702A2 (pt) | polipeptídeos de fator ix modificados e usos dos mesmos | |
| BRPI0920209A2 (pt) | conjugados de agonistas de glp-1 e usos dos mesmos | |
| BRPI0817269A2 (pt) | Análogos de azacitidina e usos dos mesmos | |
| BR112012010242A2 (pt) | derivados de heteroarilpiperidina e heteroarilpiperazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: ARACLON BIOTECH S.L. (ES) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 7/06 (2006.01), A61K 39/00 (2006.0 |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: ARACLON BIOTECH S.L. (ES) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |